Gilead Sciences, a well-known pharmaceutical company, has agreed to purchase Tubulis, a German biotechnology company, for $3.15 billion upfront. This deal expands a two-year partnership between the two companies and strengthens Gilead’s research in cancer treatments, especially in a type of therapy called antibody-drug conjugates (ADCs). ADCs combine an antibody (a protein that targets specific cells) with a drug to deliver treatment directly to cancer cells while sparing healthy cells. Tubulis has developed two promising ADC treatments. The first, called TUB-040, targets a protein called NaPi2b and is designed to treat ovarian cancer and other solid tumors. It is currently in early-stage clinical trials. The second treatment, TUB-030, targets a protein called 5T4 and has shown early potential in treating multiple types of solid tumors. Additionally, Gilead may pay Tubulis up to $1.85 billion more depending on the success of these treatments in future trials. This acquisition is the second time in recent months that Gilead has turned a partnership into a full acquisition. In February, Gilead bought Arcellx, a U.S. biotech company, for $7.8 billion to expand its portfolio of CAR-T cell therapies, which are treatments that use a patient’s own immune cells to fight cancer. Gilead also recently acquired Ouro Medicines for $2 billion, which includes a potential new treatment for immune-related diseases. Daniel O’Day, CEO of Gilead Sciences, said the agreement to acquire Tubulis is an important step forward for Gilead in cancer research. He highlighted that Tubulis brings not only a potential new treatment for ovarian cancer but also advanced ADC technology and a strong pipeline of early-stage treatments. After the deal is finalized, Tubulis will continue to operate as a research-focused organization within Gilead, with its facility in Munich, Germany, serving as a center for ADC innovation. The deal is expected to close in the second quarter of 2026, pending standard conditions.